Low frequency genetic variants in the μ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine

Neuroscience Letters

Volumn 542, Issue , 2013, Pages 71-75

  Clarke, Toni Kim ^a   Crist, Richard C ^a   Kampman, Kyle M ^a   Dackis, Charles A ^a   Pettinati, Helen M ^a   O'Brien, Charles P ^a   Oslin, David W ^a,b   Ferraro, Thomas N ^a   Lohoff, Falk W ^a   Berrettini, Wade H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Addiction; Cocaine; Genetics; Heroin; OPRM1; Rare variants

Indexed keywords

COCAINE; DIAMORPHINE; MU OPIATE RECEPTOR; OPRM1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; EUROPEAN AMERICAN; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; COCAINE-RELATED DISORDERS; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HEROIN DEPENDENCE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; RISK;

EID: 84876713797     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.02.018     Document Type: Article

References (42)

1. Adzhubei I.A., Schmidt S., Peshkin L., Ramensky V.E., Gerasimova A., Bork P., Kondrashov A.S., Sunyaev S.R. A method and server for predicting damaging missense mutations. Nat. Methods 2010, 7:248-249.
2. Arias A., Feinn R., Kranzler H.R. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend. 2006, 83:262-268.
3. Bart G., Kreek M.J., Ott J., LaForge K.S., Proudnikov D., Pollak L., Heilig M. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 2005, 30:417-422.
4. Becker A., Grecksch G., Kraus J., Loh H.H., Schroeder H., Hollt V. Rewarding effects of ethanol and cocaine in mu opioid receptor-deficient mice. Naunyn-Schmiedeberg's archives of pharmacology 2002, 365:296-302.
5. Befort K., Filliol D., Decaillot F.M., Gaveriaux-Ruff C., Hoehe M.R., Kieffer B.L. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J. Biol. Chem. 2001, 276:3130-3137.
6. Benjamini Y., Drai D., Elmer G., Kafkafi N., Golani I. Controlling the false discovery rate in behavior genetics research. Behav. Brain Res. 2001, 125:279-284.
7. Berrettini W., Yuan X., Tozzi F., Song K., Francks C., Chilcoat H., Waterworth D., Muglia P., Mooser V. Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol. Psychiatr. 2008, 13:368-373.
8. Bodmer W., Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. Nat. Genet. 2008, 40:695-701.
9. Bond C., LaForge K.S., Tian M., Melia D., Zhang S., Borg L., Gong J., Schluger J., Strong J.A., Leal S.M., Tischfield J.A., Kreek M.J., Yu L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:9608-9613.
10. Caporaso N., Gu F., Chatterjee N., Sheng-Chih J., Yu K., Yeager M., Chen C., Jacobs K., Wheeler W., Landi M.T., Ziegler R.G., Hunter D.J., Chanock S., Hankinson S., Kraft P., Bergen A.W. Genome-wide and candidate gene association study of cigarette smoking behaviors. PloS ONE 2009, 4:e4653.
11. Crowley J.J., Oslin D.W., Patkar A.A., Gottheil E., DeMaria P.A., O'Brien C.P., Berrettini W.H., Grice D.E. A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr. Genet. 2003, 13:169-173.
12. Crystal H.A., Hamon S., Randesi M., Cook J., Anastos K., Lazar J., Liu C., Pearce L., Golub E., Valcour V., Weber K.M., Holman S., Ho A., Kreek M.J. A C17T polymorphism in the mu opiate receptor is associated with quantitative measures of drug use in African American women. Addict. Biol. 2012, 17:181-191.
13. Deb I., Chakraborty J., Gangopadhyay P.K., Choudhury S.R., Das S. Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. J. Neurochem. 2010, 112:486-496.
14. Drakenberg K., Nikoshkov A., Horvath M.C., Fagergren P., Gharibyan A., Saarelainen K., Rahman S., Nylander I., Bakalkin G., Rajs J., Keller E., Hurd Y.L. Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:7883-7888.
15. Glatt S.J., Bousman C., Wang R.S., Murthy K.K., Rana B.K., Lasky-Su J.A., Zhu S.C., Zhang R., Li J., Zhang B., Li J., Lyons M.J., Faraone S.V., Tsuang M.T. Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. Drug Alcohol Depend. 2007, 90:159-165.
16. Hall F.S., Goeb M., Li X.F., Sora I., Uhl G.R. mu-Opioid receptor knockout mice display reduced cocaine conditioned place preference but enhanced sensitization of cocaine-induced locomotion. Brain Res. 2004, 121:123-130.
17. Haller G., Druley T., Vallania F.L., Mitra R.D., Li P., Akk G., Steinbach J.H., Breslau N., Johnson E., Hatsukami D., Stitzel J., Bierut L.J., Goate A.M. Rare missense variants in CHRNB4 are associated with reduced risk of nicotine dependence. Hum. Mol. Genet. 2012, 21:647-655.
18. Hasin D.S., Grant B.F., Endicott J., Harford T.C. Cocaine and heroin dependence compared in poly-drug abusers. Am. J. Public Health 1988, 78:567-569.
19. Hoehe M.R., Kopke K., Wendel B., Rohde K., Flachmeier C., Kidd K.K., Berrettini W.H., Church G.M. Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum. Mol. Genet. 2000, 9:2895-2908.
20. Kapur S., Sharad S., Singh R.A., Gupta A.K. A118g polymorphism in mu opioid receptor gene (oprm1): association with opiate addiction in subjects of Indian origin. J. Integrative Neurosci. 2007, 6:511-522.
21. Kendler K.S., Jacobson K.C., Prescott C.A., Neale M.C. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am. J. Psychiatr. 2003, 160:687-695.
22. Kroslak T., Laforge K.S., Gianotti R.J., Ho A., Nielsen D.A., Kreek M.J. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J. Neurochem. 2007, 103:77-87.
23. Kumar D., Chakraborty J., Das S. Epistatic effects between variants of kappa-opioid receptor gene and A118G of mu-opioid receptor gene increase susceptibility to addiction in Indian population. Prog Neuro Psychopharmacol. Biol. Psychiatr. 2012, 36:225-230.
24. Lauzon P., Vincelette J., Bruneau J., Lamothe F., Lachance N., Brabant M., Soto J. Illicit use of methadone among i.v. drug users in Montreal. J. Subst. Abuse Treat. 1994, 11:457-461.
25. Levran O., Londono D., O'Hara K., Nielsen D.A., Peles E., Rotrosen J., Casadonte P., Linzy S., Randesi M., Ott J., Adelson M., Kreek M.J. Genetic susceptibility to heroin addiction: a candidate gene association study. Genes, brain, and behavior 2008, 7:720-729.
26. Luo X., Kranzler H.R., Zhao H., Gelernter J. Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 120B:97-108.
27. Matthes H.W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dolle P., Tzavara E., Hanoune J., Roques B.P., Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996, 383:819-823.
28. Nielsen D.A., Ji F., Yuferov V., Ho A., Chen A., Levran O., Ott J., Kreek M.J. Genotype patterns that contribute to increased risk for or protection from developing heroin addiction. Mol. Psychiatr. 2008, 13:417-428.
29. Oertel B.G., Kettner M., Scholich K., Renne C., Roskam B., Geisslinger G., Schmidt P.H., Lotsch J. A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J. Biol. Chem. 2009, 284:6530-6535.
30. Piestrzeniewicz M.K., Fichna J., Janecka A. Opioid receptors and their selective ligands. Postepy Biochem. 2006, 52:313-319.
31. Ravindranathan A., Joslyn G., Robertson M., Schuckit M.A., Whistler J.L., White R.L. Functional characterization of human variants of the mu-opioid receptor gene. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:10811-10816.
32. Saccone S.F., Hinrichs A.L., Saccone N.L., Chase G.A., Konvicka K., Madden P.A., Breslau N., Johnson E.O., Hatsukami D., Pomerleau O., Swan G.E., Goate A.M., Rutter J., Bertelsen S., Fox L., Fugman D., Martin N.G., Montgomery G.W., Wang J.C., Ballinger D.G., Rice J.P., Bierut L.J. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum. Mol. Genet. 2007, 16:36-49.
33. Tan E.C., Tan C.H., Karupathivan U., Yap E.P. Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport 2003, 14:569-572.
34. Tsuang M.T., Lyons M.J., Eisen S.A., Goldberg J., True W., Lin N., Meyer J.M., Toomey R., Faraone S.V., Eaves L. Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs. Am. J. Med. Genet. 1996, 67:473-477.
35. Tsuang M.T., Lyons M.J., Meyer J.M., Doyle T., Eisen S.A., Goldberg J., True W., Lin N., Toomey R., Eaves L. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch. Gen. Psychiatr. 1998, 55:967-972.
36. Wessel J., McDonald S.M., Hinds D.A., Stokowski R.P., Javitz H.S., Kennemer M., Krasnow R., Dirks W., Hardin J., Pitts S.J., Michel M., Jack L., Ballinger D.G., McClure J.B., Swan G.E., Bergen A.W. Resequencing of nicotinic acetylcholine receptor genes and association of common and rare variants with the Fagerstrom test for nicotine dependence. Neuropsychopharmacology 2010, 35:2392-2402.
37. Xie P., Kranzler H.R., Krauthammer M., Cosgrove K.P., Oslin D., Anton R.F., Farrer L.A., Picciotto M.R., Krystal J.H., Zhao H., Gelernter J. Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. Biol. Psychiatr. 2011, 70:528-536.
38. Xuei X., Flury-Wetherill L., Bierut L., Dick D., Nurnberger J., Foroud T., Edenberg H.J. The opioid system in alcohol and drug dependence: family-based association study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B:877-884.
39. Zhang D., Shao C., Shao M., Yan P., Wang Y., Liu Y., Liu W., Lin T., Xie Y., Zhao Y., Lu D., Li Y., Jin L. Effect of mu-opioid receptor gene polymorphisms on heroin-induced subjective responses in a Chinese population. Biol. Psychiatr. 2007, 61:1244-1251.
40. Zhang H., Luo X., Kranzler H.R., Lappalainen J., Yang B.Z., Krupitsky E., Zvartau E., Gelernter J. Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum. Mol. Genet. 2006, 15:807-819.
41. Zhang Y., Wang D., Johnson A.D., Papp A.C., Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J. Biol. Chem. 2005, 280:32618-32624.
42. Zubieta J.K., Gorelick D.A., Stauffer R., Ravert H.T., Dannals R.F., Frost J.J. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat. Med. 1996, 2:1225-1229.